Novel Drug Delivery Systems Approved by USFDA from 2019 to 2023: A Comprehensive Review.

Abstract

In recent years, tremendous progress in the field of novel drug delivery systems (NDDS), which has prompted the creation of new strategies to enhance treatment results and patient compliance. The goal of this comprehensive review is to provide a summary of the NDDS that the US Food and Drug Administration (USFDA) has approved from 2019 to 2023. Various databases, including PubMed, Scopus, USFDA, and patent websites were utilized to gather relevant information. The selected NDDSs were categorized based on their delivery route, such as oral, injectable, transdermal, pulmonary, nasal, ocular, and implantable. For each delivery route, the review provides a detailed analysis of the approved NDDSs, including their mechanisms of action, advantages, limitations, and clinical applications. Additionally, the review discusses the challenges faced during the development and commercialization of these systems, as well as the prospects and potential areas of improvement. The findings of this comprehensive review demonstrate the remarkable progress made in the field of NDDSs, with the USFDA approving several innovative technologies in recent years. The approved NDDSs have shown promising results in enhancing drug stability, bioavailability, and controlled release, leading to improved therapeutic outcomes and patient convenience. In conclusion, this comprehensive review provides a valuable resource for researchers, healthcare professionals, and pharmaceutical industries, offering insights into the latest advancements in NDDSs approved by the US FDA. The knowledge gained from this review can guide future research endeavors, foster innovation, and contribute to developing more effective and patient-friendly NDDS strategies.